Revelation Biosciences, Inc. (REVB)
US — Healthcare Sector
Automate Your Wheel Strategy on REVB
With Tiblio's Option Bot, you can configure your own wheel strategy including REVB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REVB
- Rev/Share 0.0278
- Book/Share 2.9658
- PB 0.9525
- Debt/Equity 0.0
- CurrentRatio 3.6052
- ROIC -2.8354
- MktCap 1911392.0
- FreeCF/Share -23.9667
- PFCF -0.0821
- PE -0.1904
- Debt/Assets 0.0
- DivYield 0
- ROE -5.0544
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Revelation Biosciences, Inc. (REVB)
- IPO Date 2020-11-17
- Website https://www.revbiosciences.com
- Industry Biotechnology
- CEO James M. Rolke
- Employees 8
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.